238 Results for "

degeneration

" in MedChemExpress (MCE) Product Catalog:
Products (238)

238 Results for "degeneration" in MCE Product Catalog:

305
305 Publications Verification
Cat. No.: HY-B0146
CAS No.: 129497-78-5
Synonyms: CL 318952
Research Areas:  

Cancer

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-129241
CAS No.: 330834-54-3
Purity:  99.33%
AGX51 is a pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist that disrupts ID-E protein interactions, thereby triggering ubiquitin-mediated proteasomal degradation of ID1, ID2, ID3 and ID4. AGX51 induces ROS production, G0/G1 cell cycle arrest, non-apoptotic cell death, and regulates EMT-related proteins. AGX51 reduces the proliferation, migration and myofibroblast differentiation of lung fibroblasts, alleviates pulmonary fibrosis, inhibits cancer cell viability and tumor growth, impairs neovascularization, and shows no obvious toxicity in mice. AGX51 can be used in research related to idiopathic pulmonary fibrosis, triple-negative breast cancer, breast cancer, pancreatic ductal adenocarcinoma, colorectal tumors, wet age-related macular degeneration and retinopathy of prematurity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-154919
Purity:  99.52%
Research Areas:  

Endocrinology Cancer

DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N2259
CAS No.: 19431-84-6
Synonyms: (+)-Curcumenol
Curcumenol ((+)-Curcumenol) is a natural compound with oral efficacy, exhibiting an IC50 of 12.6 μM and a Ki of 10.8 μM against human CYP3A4. Curcumenol inhibits TNFα-induced phosphorylation/degradation of IκBα, phosphorylation/nuclear translocation of NF-κB p65, as well as the upregulation of MMP3, MMP9, MMP13, TRAF3, IL1RL1, TNFα and IL-1β. Curcumenol suppresses LPS-induced phosphorylation of Akt and p38 MAPK, as well as the production of pro-inflammatory mediators/proteins, and downregulates the SLC7A11/NF-κB/TGF-β pathway. Curcumenol binds to and inhibits the activation of Fyn and Lyn, blocks the function of downstream FcεRI signaling components, and reduces the release of allergic mediators/cytokines. Curcumenol upregulates the expression of KDM6B, and promotes chondrocyte proliferation and cartilage repair. Curcumenol induces ferroptosis and apoptosis, regulates the EMT process, and inhibits tumor growth and metastasis of triple-negative breast cancer. Curcumenol possesses anti-inflammatory, neuroprotective, antioxidant, antitumor, antiviral and hepatoprotective activities. Curcumenol can be used in research related to intervertebral disc degeneration, cancer, inflammation, central nervous system neurodegenerative diseases, allergic reactions and knee osteoarthritis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-128973
CAS No.: 24533-72-0
Purity:  ≥98.0%
Research Areas:  

Cancer

Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-110195
CAS No.: 1007647-73-5
Purity:  99.81%
Synonyms: A01
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0723
CAS No.: 128607-22-7
Synonyms: FC-1271a
Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with Ki values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112499
CAS No.: 2124-57-4
Purity:  ≥98.0%
Synonyms: Vitamin K2-7; Vitamin K2(35); Vitamin MK-7
Target:  

TGF-beta/Smad

Research Areas:  

Cardiovascular Disease

Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9951A
CAS No.: 347396-82-1
Synonyms: RG-6321 (anti-VEGF)

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114775
CAS No.: 108237-91-8
Purity:  99.92%
RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-124876
CAS No.: 685121-45-3
Purity:  99.89%
Synonyms: SC-D
Target:  

α-synuclein

Research Areas:  

Neurological Disease

SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P3252A
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101318
CAS No.: 72786-10-8
Purity:  98.0%
Synonyms: β-FNA hydrochloride
β-Funaltrexamine (β-FNA) hydrochloride is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine hydrochloride inhibits p38 MAPK and TLR4 signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine hydrochloride inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine hydrochloride is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99905
CAS No.: 2375661-82-6
Synonyms: IBI302

Target:  

VEGFR

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3204
CAS No.: 934461-40-2
Synonyms: AL-78898A
Target:  

Complement System

Research Areas:  

Metabolic Disease

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101446
CAS No.: 314054-36-9
Purity:  99.94%
Target:  

Trk Receptor ERK Apoptosis

Research Areas:  

Neurological Disease

HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16959
CAS No.: 816432-15-2
Target:  

Inhibitory Antibodies

Research Areas:  

Others

CEP dipeptide 1 is a CEP dipeptide with potent angiogenic activity; mediators of age-related macular degeneration (AMD).
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109020
CAS No.: 1229453-99-9
Purity:  99.84%
Synonyms: LHA510
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Acrizanib (LHA510) is a small-molecule vascular endothelial growth factor receptor 2 (VEGFR-2, KDR) inhibitor. Acrizanib inhibits the proliferation of BaF3-Tel-KDR cells dependent on VEGFR-2 activity, with an IC50 of 17.4 nM. Acrizanib can be used in research related to choroidal neovascularization and neovascular age-related macular degeneration .
loading...
    loading...